报价延迟最少15分钟:2026/04/23 02:45 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
40.27 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.66/-1.53
|
|
企业价值
2.95B
|
| 资产负债 |
|
每股账面净值
8.43
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
